Sanofi to buy Kymab for $1.45B

  • Sanofi will acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
  • The transaction will result in Sanofi having full global rights to KY1005, a fully human monoclonal antibody that has a novel mechanism of action. KY1005 binds to OX40-Ligand and has the potential to treat a wide variety of immune-mediated diseases and inflammatory disorders
  • The Kymab acquisition adds KY1005 to Sanofi’s dynamic pipeline, a potential first-in-class treatment for a range of immune and inflammatory diseases
  • In August 2020, Kymab announced that KY1005 met both primary endpoints in a Phase 2a trial studying moderate to severe atopic dermatitis patients whose disease is inadequately controlled with topical corticosteroids
  • This acquisition aligns with Sanofi’s strategy of targeting fundamentally important disease pathways
  • Kymab’s pipeline also includes the oncology asset KY1044, an ICOS agonist monoclonal antibody, currently in early Phase 1/2 development as monotherapy and in combination with an anti-PD-L1

    Saonfi fundamentals

    Investors in Sanofi-Aventis can expect a huge dividend payment. Based on the recent analysts' consensus the stock now has one of the highest dividend returns of the French market. Per share the analysts expect a dividend of 3.21 euros per share. Sanofi-Aventis 's dividend yield thus equals 3.94 percent. The average dividend yield of the pharmaceutical companies is a moderate 0.16 percent.

    Historical dividend returns Sanofi-Aventis

    For this year the company, located in Parijs revenue will be around 36.75 billion euros. This is according to the average of the analysts' estimates. This is slightly lower than 2019's revenue of 37.63 billion euros.

    Historical revenues and results Sanofi-Aventis plus estimates 2020

    beurskoersSanofi

    The analysts expect for 2020 a net profit of 7.3 billion euros. For this year the majority of the analysts, consulted by press agency Thomson Reuters, expects a profit per share of 5.78 euros. Based on this the price/earnings-ratio is 14.09.

    Recent target prices around 103 euros

    The most recent recommendations for the pharmaceutical company are from Credit Suisse , Goldman Sachs and Jefferies & Co..

    Sanofi-Aventis 's market capitalization is based on the number of outstanding shares around 101.4 billion euros. The Sanofi-Aventis stock was the past 12 months quite unstable. Since last January the stock is 5 percent lower. This year the stock price moved between 68 and 96 euro.

    Historical stock prices Sanofi-Aventis past 10 years

    stock price sanofi-aventis

    Click here for dividend Sanofi-Aventis. At 12.10 the stock trades 0.75 percent lower at 81.42 euros.

    Analist.nl Nieuwsdienst: +31 084-0032-842
    nieuws@analist.nl

    Copyright analist.nl B.V.
    All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.